US 12,128,098 B2
Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
Hugh McTavish, Pine Springs, MN (US)
Assigned to Squarex, LLC, Pine Springs, MN (US)
Filed by Squarex, LLC, Pine Springs, MN (US)
Filed on Jan. 28, 2021, as Appl. No. 17/160,776.
Application 17/160,776 is a continuation of application No. 15/681,393, filed on Aug. 20, 2017, granted, now 10,245,314.
Application 17/160,776 is a continuation of application No. 16/259,922, filed on Jan. 28, 2019, granted, now 10,940,197.
Application 15/681,393 is a continuation of application No. PCT/US2016/019978, filed on Feb. 26, 2016.
Claims priority of provisional application 62/120,973, filed on Feb. 26, 2015.
Prior Publication US 2021/0145962 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/245 (2006.01); A61K 9/00 (2006.01); A61K 31/04 (2006.01); A61K 31/122 (2006.01); A61K 31/215 (2006.01); A61K 35/763 (2015.01); A61K 39/12 (2006.01); A61K 39/165 (2006.01); C07K 14/035 (2006.01); G01N 33/571 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/245 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0021 (2013.01); A61K 31/04 (2013.01); A61K 31/122 (2013.01); A61K 31/215 (2013.01); A61K 35/763 (2013.01); A61K 39/12 (2013.01); A61K 39/165 (2013.01); C07K 14/035 (2013.01); G01N 33/571 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55511 (2013.01); C12N 2710/16611 (2013.01)] 19 Claims
 
1. A method of treating herpes simplex virus (HSV) infection comprising:
an administering step comprising:
applying a topical immunosensitizer to the skin of a person infected with HSV at a time when the person is not having an HSV outbreak, or applying a topical immunosensitizer to the skin of a person infected with HSV during an HSV outbreak wherein the applying is at a site other than a site of an HSV lesion;
wherein the method does not further comprise (i) applying a topical immunosensitizer to the skin of a person infected with HSV on an HSV lesion at a time of an HSV outbreak in the person; or (ii) intradermally injecting a recall antigen into a person infected with HSV in an HSV lesion at the time of an HSV outbreak in the person;
wherein the topical immunosensitizer comprises a squaric acid ester, diphenylcyclopropenone (DPCP), 1-chloro-2,4-dinitrobenzene (DNCB), or 1-chloro-2,6-dinitrobenzene;
wherein the method reduces the frequency of HSV outbreaks in the person after the administering step;
wherein the person has had HSV outbreaks before the administering step and is in recognized need of treatment for HSV infection;
wherein the person has genital herpes.